Phase II study of stereotactic radiotherapy for kidney cancer using an MR-Linac system
Phase 2
Recruiting
- Conditions
- Kidney cancer(primary kidney cancer)
- Registration Number
- JPRN-UMIN000045721
- Lead Sponsor
- Tohoku University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Radiation oncologists judge not to have a tolerance or not to be suitable for stereotacitc radiotherapy because of coexisting illness (2)Double cancer or past history of double cancer within 3 years. (3)Implanted metal in the body (4)Mental disorder, especially claustrophobiady (5)Infection (6)Pregnant or lactating woman, likelihood of pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method One-year local control and the rate of occurrence of serious adverse event.
- Secondary Outcome Measures
Name Time Method One-year overall survival and 1-year progression free survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie MR-Linac stereotactic radiotherapy efficacy in primary kidney cancer?
How does MR-Linac based stereotactic radiotherapy compare to conventional SRS for renal cell carcinoma outcomes?
Which biomarkers correlate with response to MR-guided stereotactic radiotherapy in clear cell renal cell carcinoma?
What are the acute and late adverse events associated with MR-Linac kidney cancer radiotherapy protocols?
Are there synergistic combination therapies with MR-Linac stereotactic radiotherapy for VHL-negative kidney tumors?